|
1
|
Koga Y and Ochiai A: Systematic review of
patient-derived xenograft models for preclinical studies of
anti-cancer drugs in solid tumors. Cells. 8(pii): E4182019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Witt Hamer PC, Van Tilborg AA, Eijk PP,
Sminia P, Troost D, Van Noorden CJ, Ylstra B and Leenstra S: The
genomic profile of human malignant glioma is altered early in
primary cell culture and preserved in spheroids. Oncogene.
27:2091–2096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee J, Kotliarova S, Kotliarov Y, Li A, Su
Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al:
Tumor stem cells derived from glioblastomas cultured in bFGF and
EGF more closely mirror the phenotype and genotype of primary
tumors than do serum-cultured cell lines. Cancer Cell. 9:391–403.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Laks DR, Crisman TJ, Shih MY, Mottahedeh
J, Gao F, Sperry J, Garrett MC, Yong WH, Cloughesy TF, Liau LM, et
al: Large-scale assessment of the gliomasphere model system. Neuro
Oncol. 18:1367–1378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wakimoto H, Mohapatra G, Kanai R, Curry WT
Jr, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO,
Louis DN, et al: Maintenance of primary tumor phenotype and
genotype in glioblastoma stem cells. Neuro Oncol. 14:132–144. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gargiulo G: Next-generation in vivo
modeling of human cancers. Front Oncol. 8:4292018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patel P, Baradaran H, Delgado D, Askin G,
Christos P, John Tsiouris A and Gupta A: MR perfusion-weighted
imaging in the evaluation of high-grade gliomas after treatment: A
systematic review and meta-analysis. Neuro Oncol. 19:118–127. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suh CH, Kim HS, Jung SC, Choi CG and Kim
SJ: Perfusion MRI as a diagnostic biomarker for differentiating
glioma from brain metastasis: A systematic review and
meta-analysis. Eur Radiol. 28:3819–3831. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aquino D, Gioppo A, Finocchiaro G,
Bruzzone MG and Cuccarini V: MRI in Glioma immunotherapy: Evidence,
pitfalls, and perspectives. J Immunol Res. 2017:58139512017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pope WB and Brandal G: Conventional and
advanced magnetic resonance imaging in patients with high-grade
glioma. Q J Nucl Med Mol Imaging. 62:239–253. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Minosse S, Marzi S, Piludu F and Vidiri A:
Correlation study between DKI and conventional DWI in brain and
head and neck tumors. Magn Reson Imaging. 42:114–122. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sinkus R, Van Beers BE, Vilgrain V,
DeSouza N and Waterton JC: Apparent diffusion coefficient from
magnetic resonance imaging as a biomarker in oncology drug
development. Eur J Cancer. 48:425–431. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Liu H, Tong H, Wang S, Yang Y,
Liu G and Zhang W: Clinical applications of contrast-enhanced
perfusion MRI techniques in gliomas: Recent advances and current
challenges. Contrast Media Mol Imaging. 2017:70641202017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bernstein JM, Homer JJ and West CM:
Dynamic contrast-enhanced magnetic resonance imaging biomarkers in
head and neck cancer: Potential to guide treatment? A systematic
review. Oral Oncol. 50:963–970. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo H, Kang H, Tong H, Du X, Liu H, Tan Y,
Yang Y, Wang S and Zhang W: Microvascular characteristics of
lower-grade diffuse gliomas: Investigating vessel size imaging for
differentiating grades and subtypes. Eur Radiol. 29:1893–1902.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Linnik IV, Scott ML, Holliday KF,
Woodhouse N, Waterton JC, O'Connor JP, Barjat H, Liess C, Ulloa J,
Young H, et al: Noninvasive tumor hypoxia measurement using
magnetic resonance imaging in murine U87 glioma xenografts and in
patients with glioblastoma. Magn Reson Med. 71:1854–1862. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahn SS, Shin NY, Chang JH, Kim SH, Kim EH,
Kim DW and Lee SK: Prediction of methylguanine methyltransferase
promoter methylation in glioblastoma using dynamic
contrast-enhanced magnetic resonance and diffusion tensor imaging.
J Neurosurg. 121:367–373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smits M and van den Bent MJ: Imaging
correlates of adult glioma genotypes. Radiology. 284:316–331. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Dijken BRJ, van Laar PJ, Holtman GA
and van der Hoorn A: Diagnostic accuracy of magnetic resonance
imaging techniques for treatment response evaluation in patients
with high-grade glioma, a systematic review and meta-analysis. Eur
Radiol. 27:4129–4144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Workman P, Aboagye EO, Balkwill F, Balmain
A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA,
Glennie MJ, et al: Guidelines for the welfare and use of animals in
cancer research. Br J Cancer. 102:1555–1577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jackson A, O'Connor JP, Parker GJ and
Jayson GC: Imaging tumor vascular heterogeneity and angiogenesis
using dynamic contrast-enhanced magnetic resonance imaging. Clin
Cancer Res. 13:3449–3459. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sourbron SP and Buckley DL: Classic models
for dynamic contrast-enhanced MRI. NMR Biomed. 26:1004–1027. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pollard SM, Yoshikawa K, Clarke ID, Danovi
D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, et
al: Glioma stem cell lines expanded in adherent culture have
tumor-specific phenotypes and are suitable for chemical and genetic
screens. Cell Stem Cell. 4:568–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cárdenas-Rodríguez J, Howison CM and Pagel
MD: A linear algorithm of the reference region model for DCE-MRI is
robust and relaxes requirements for temporal resolution. Magn Reson
Imaging. 31:497–507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xue W, Du X, Wu H, Liu H, Xie T, Tong H,
Chen X, Guo Y and Zhang W: Aberrant glioblastoma neovascularization
patterns and their correlation with DCE-MRI-derived parameters
following temozolomide and bevacizumab treatment. Sci Rep.
7:138942017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The Gene
Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
The Gene Ontology Consortium, . The Gene
Ontology Resource: 20 years and still GOing strong. Nucleic Acids
Res. 47:D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Joo KM, Kim J, Jin J, Kim M, Seol HJ,
Muradov J, Yang H, Choi YL, Park WY, Kong DS, et al:
Patient-specific orthotopic glioblastoma xenograft models
recapitulate the histopathology and biology of human glioblastomas
in situ. Cell Rep. 3:260–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boult JKR, Apps JR, Hölsken A, Hutchinson
JC, Carreno G, Danielson LS, Smith LM, Bäuerle T, Buslei R,
Buchfelder M, et al: Preclinical transgenic and patient-derived
xenograft models recapitulate the radiological features of human
adamantinomatous craniopharyngioma. Brain Pathol. 28:475–483. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wong K, Young GS, Makale M, Hu X, Yildirim
N, Cui K, Wong ST and Kesari S: Characterization of a human
tumorsphere glioma orthotopic model using magnetic resonance
imaging. J Neurooncol. 104:473–481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lenting K, Verhaak R, Ter Laan M,
Wesseling P and Leenders W: Glioma: Experimental models and
reality. Acta Neuropathol. 133:263–282. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Garcia-Romero N, Gonzalez-Tejedo C,
Carrión-Navarro J, Esteban-Rubio S, Rackov G, Rodríguez-Fanjul V,
Oliver-De La Cruz J, Prat-Acín R, Peris-Celda M, Blesa D, et al:
Cancer stem cells from human glioblastoma resemble but do not mimic
original tumors after in vitro passaging in serum-free media.
Oncotarget. 7:65888–65901. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu WW, Li B, Guan XY, Chung SK, Wang Y,
Yip YL, Law SY, Chan KT, Lee NP, Chan KW, et al: Cancer
cell-secreted IGF2 instigates fibroblasts and bone marrow-derived
vascular progenitor cells to promote cancer progression. Nat
Commun. 8:143992017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Terai S, Fushida S, Tsukada T, Kinoshita
J, Oyama K, Okamoto K, Makino I, Tajima H, Ninomiya I, Fujimura T,
et al: Bone marrow derived ‘fibrocytes’ contribute to tumor
proliferation and fibrosis in gastric cancer. Gastric Cancer.
18:306–313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hutterer M, Hattingen E, Palm C,
Proescholdt MA and Hau P: Current standards and new concepts in MRI
and PET response assessment of antiangiogenic therapies in
high-grade glioma patients. Neuro Oncol. 17:784–800. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reyes-Botero G, Dehais C, Idbaih A,
Martin-Duverneuil N, Lahutte M, Carpentier C, Letouzé E, Chinot O,
Loiseau H, Honnorat J, et al: Contrast enhancement in
1p/19q-codeleted anaplastic oligodendrogliomas is associated with
9p loss, genomic instability, and angiogenic gene expression. Neuro
Oncol. 16:662–670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu X, Li Y, Sun Z, Li S, Wang K, Fan X,
Liu Y, Wang L, Wang Y and Jiang T: Molecular profiles of tumor
contrast enhancement: A radiogenomic analysis in anaplastic
gliomas. Cancer Med. 7:4273–4283. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kickingereder P, Wiestler B, Graf M,
Heiland S, Schlemmer HP, Wick W, Wick A, Bendszus M and Radbruch A:
Evaluation of dynamic contrast-enhanced MRI derived microvascular
permeability in recurrent glioblastoma treated with bevacizumab. J
Neurooncol. 121:373–380. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Robba T, Chianca V, Albano D, Clementi V,
Piana R, Linari A, Comandone A, Regis G, Stratta M, Faletti C and
Borrè A: Diffusion-weighted imaging for the cellularity assessment
and matrix characterization of soft tissue tumour. Radiol Med.
122:871–879. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schob S, Surov A, Wienke A, Meyer HJ,
Spielmann RP and Fiedler E: Correlation Between aquaporin 4
expression and different DWI parameters in grade I meningioma. Mol
Imaging Biol. 19:138–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tse V, Xu L, Yung YC, Santarelli JG, Juan
D, Fabel K, Silverberg G and Harsh G IV: The temporal-spatial
expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor
angiogenesis and their functional correlation with tumor
neovascular architecture. Neurol Res. 25:729–738. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nikbakht H, Panditharatna E, Mikael LG, Li
R, Gayden T, Osmond M, Ho CY, Kambhampati M, Hwang EI, Faury D, et
al: Spatial and temporal homogeneity of driver mutations in diffuse
intrinsic pontine glioma. Nat Commun. 7:111852016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Phillips LM, Zhou X, Cogdell DE, Chua CY,
Huisinga A, R Hess K, Fuller GN and Zhang W: Glioma progression is
mediated by an addiction to aberrant IGFBP2 expression and can be
blocked using anti-IGFBP2 strategies. J Pathol. 239:355–364. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gilbert MR, Dignam JJ, Armstrong TS, Wefel
JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S,
Won M, et al: A randomized trial of bevacizumab for newly diagnosed
glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schäfer N, Gielen GH, Kebir S, Wieland A,
Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, et al:
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J
Cancer Res Clin Oncol. 142:1581–1589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Baysan M, Woolard K, Bozdag S, Riddick G,
Kotliarova S, Cam MC, Belova GI, Ahn S, Zhang W, Song H, et al:
Micro-environment causes reversible changes in DNA methylation and
mRNA expression profiles in patient-derived glioma stem cells. PLoS
One. 9:e940452014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang D, Li JR, Zhang YH, Chen L, Huang T
and Cai YD: Identification of differentially expressed genes
between original breast cancer and xenograft using machine learning
algorithms. Genes (Basel). 9(pii): E1552018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Siegelin MD, Raskett CM, Gilbert CA, Ross
AH and Altieri DC: Sorafenib exerts anti-glioma activity in vitro
and in vivo. Neurosci Lett. 478:165–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yan D, Kowal J, Akkari L, Schuhmacher AJ,
Huse JT, West BL and Joyce JA: Inhibition of colony stimulating
factor-1 receptor abrogates microenvironment-mediated therapeutic
resistance in gliomas. Oncogene. 36:6049–6058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Galanis E, Anderson SK, Lafky JM, Uhm JH,
Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle
KA, et al: Phase II study of bevacizumab in combination with
sorafenib in recurrent glioblastoma (N0776): A north central cancer
treatment group trial. Clin Cancer Res. 19:4816–4823. 2013.
View Article : Google Scholar : PubMed/NCBI
|
